Last edition
News about "Duchenne muscular dystrophy "
Atossa Therapeutics Receives FDA Orphan Drug Designation for Duchenne Therapy
Atossa Therapeutics has received US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy, further supporting the company’s development programme in rare paediatric neuromuscular diseases.
Duchenne Muscular Dystrophy | 17/01/2026 | By News Bureau
Sarepta Pauses Shipments of Duchenne Gene Therapy Elevidys Amid FDA Safety Review
Sarepta Therapeutics has announced a voluntary and temporary suspension of all US shipments of its Duchenne muscular dystrophy (DMD) gene therapy, ELEVIDYS (delandistrogene moxeparvovec), following the FDA’s distribution suspension request last week.
Duchenne Muscular Dystrophy | 24/07/2025 | By Dineshwori | 375
Somite Therapeutics Receives FDA Orphan Drug and RPDD Designations for SMT-M01
Somite Therapeutics' SMT-M01 program leverages the company's proprietary AlphaStem AI platform to develop a novel cell replacement therapy for DMD.
Duchenne Muscular Dystrophy | 17/09/2024 | By Aishwarya | 664
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy